TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women
Brief Summary: The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.


Options:
A: Arm Label: CO2 fractionated vaginal laser; Type: EXPERIMENTAL; Interventions: Device: CO2 fractionated vaginal laser | Arm Label: Estrogens, Conjugated (USP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Estrogens, Conjugated (USP) | Intervention Type: DEVICE; Name: CO2 fractionated vaginal laser; Assigned to Arm(s): CO2 fractionated vaginal laser | Intervention Type: DRUG; Name: Estrogens, Conjugated (USP); Assigned to Arm(s): Estrogens, Conjugated (USP)
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: 17-b-estradiol, Drug: 17-b-estradiol + medroxyprogeterone acetate, Drug: 17-b-estradiol hemihydrate, Drug: placebo pill + gel | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 17-b-estradiol, Drug: 17-b-estradiol + medroxyprogeterone acetate, Drug: 17-b-estradiol hemihydrate, Drug: placebo pill + gel | Intervention Type: DRUG; Name: 17-b-estradiol; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 17-b-estradiol + medroxyprogeterone acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 17-b-estradiol hemihydrate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: placebo pill + gel; Assigned to Arm(s): 1, 2
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conjugated equine estrogens 0.45 mg/day, Drug: Transdermal estradiol, 50 mcg/day, Drug: Micronized progesterone, 200 mg/day x 12 d/month, Drug: CEE, progesterone, transdermal patch or the placebo | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: CEE , progesterone, estradiol patch or placebo for each, Drug: CEE, progesterone, transdermal patch or the placebo | Intervention Type: DRUG; Name: Conjugated equine estrogens 0.45 mg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Transdermal estradiol, 50 mcg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Micronized progesterone, 200 mg/day x 12 d/month; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CEE , progesterone, estradiol patch or placebo for each; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: CEE, progesterone, transdermal patch or the placebo; Assigned to Arm(s): Arm 1, Arm 2
D: Arm Label: Treatment with transdermal 17β-estradiol; Type: EXPERIMENTAL; Interventions: Drug: 17β-estradiol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: 17β-estradiol | Intervention Type: DRUG; Name: 17β-estradiol; Assigned to Arm(s): Control, Treatment with transdermal 17β-estradiol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a CNI-free Regimen With Enteric-Coated Mycophenolate Sodium (EC-MPS) and Everolimus in Comparison to Standard Therapy With Enteric-Coated Mycophenolate Sodium (EC-MPS) and Cyclosporine Microemulsion in de Novo Renal Transplant Patients
Brief Summary: The purpose of this study is to assess whether a calcineurin inhibitor (CNI)-free regimen with enteric-coated mycophenolate sodium (EC-MPS) and everolimus is as safe and well-tolerated as the standard regimen containing enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine microemulsion, but results in better renal function.


Options:
A: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A
B: Arm Label: Everolimus + Mycophenolate sodium; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Enteric-coated mycophenolate sodium, Drug: Corticosteroids | Arm Label: Cyclosporine + Mycophenolate sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporine, Drug: Enteric-coated mycophenolate sodium, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + Mycophenolate sodium | Intervention Type: DRUG; Name: Cyclosporine; Assigned to Arm(s): Cyclosporine + Mycophenolate sodium | Intervention Type: DRUG; Name: Enteric-coated mycophenolate sodium; Assigned to Arm(s): Cyclosporine + Mycophenolate sodium, Everolimus + Mycophenolate sodium | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Cyclosporine + Mycophenolate sodium, Everolimus + Mycophenolate sodium
C: Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): N/A
D: Arm Label: Standard dose EC-MPS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enteric-coated mycophenolate sodium (EC-MPS), Drug: Tacrolimus, Drug: Corticosteroids | Arm Label: High EC-MPS; Type: EXPERIMENTAL; Interventions: Drug: Enteric-coated mycophenolate sodium (EC-MPS), Drug: Tacrolimus, Drug: Corticosteroids | Intervention Type: DRUG; Name: Enteric-coated mycophenolate sodium (EC-MPS); Assigned to Arm(s): High EC-MPS, Standard dose EC-MPS | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): High EC-MPS, Standard dose EC-MPS | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): High EC-MPS, Standard dose EC-MPS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer
Brief Summary: Based on a universal eradication of H. pylori in an offshore island (Matsu) with a high prevalence of gastric cancer as well as premalignant gastric lesion, we first examined the infection rate of H. pylori. Secondly, we evaluated the efficacy of clarithromycin-based triple therapy with a levofloxacin-based rescue treatment. And thirdly, we tested the hypothesis that whether the cure of H. pylori can reverse the premalignant gastric lesion. Fourth, we determine the cost-effectiveness of this intervention. The gene-environment interaction will be addressed regarding gastric cancer carcinogenesis. Finally, the incident rate of gastric cancer would be followed in this cohort.


Options:
A: Arm Label: H pylori eradication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Helicobacter pylori eradication | Intervention Type: DRUG; Name: Helicobacter pylori eradication; Assigned to Arm(s): H pylori eradication
B: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: treatment group; Type: ACTIVE_COMPARATOR; Interventions: Drug: eradication treatment of Helicobacter pylori infection | Intervention Type: DRUG; Name: eradication treatment of Helicobacter pylori infection; Assigned to Arm(s): treatment group
C: Arm Label: 7 day H.pylori eradication; Type: ACTIVE_COMPARATOR; Interventions: Drug: 7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Omeprazole or Rabeprazole, Clarithromycin | Intervention Type: DRUG; Name: 7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin; Assigned to Arm(s): 7 day H.pylori eradication | Intervention Type: DRUG; Name: Placebo, Omeprazole or Rabeprazole, Clarithromycin; Assigned to Arm(s): Placebo
D: Arm Label: Group 1:Triple therapy; Type: EXPERIMENTAL; Interventions: Drug: Triple therapy | Arm Label: Group 2:No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Triple therapy; Assigned to Arm(s): Group 1:Triple therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis Patients
Brief Summary: Sleep disturbance is prevalent in chronic dialysis patients and there is a negative correlation between the quality of life and overall survival and sleep disturbance in them. Cognitive-behavioral therapy is an effective behavioral therapy for insomnia clinically. In previous studies, cognitive-behavioral therapy can redress anxiety in chronic hemodialysis patients. This study tries to elucidate its therapeutic effect on the sleep disturbance in chronic peritoneal dialysis patients.


Options:
A: Arm Label: Cohort 1 (RO0503821 [0.25/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 2 (RO0503821 [0.25/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 3 (RO0503821 [0.4/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 4 (RO0503821 [0.4/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 5 (RO0503821 [0.6/150 1x/week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Cohort 6 (RO0503821 [0.6/150 1x/2week]); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): Cohort 1 (RO0503821 [0.25/150 1x/week]), Cohort 2 (RO0503821 [0.25/150 1x/2week]), Cohort 3 (RO0503821 [0.4/150 1x/week]), Cohort 4 (RO0503821 [0.4/150 1x/2week]), Cohort 5 (RO0503821 [0.6/150 1x/week]), Cohort 6 (RO0503821 [0.6/150 1x/2week])
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nocturnal home hemodialysis | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nocturnal home hemodialysis | Intervention Type: BEHAVIORAL; Name: Nocturnal home hemodialysis; Assigned to Arm(s): 1, 2
C: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).
Brief Summary: A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy (DPN).


Options:
A: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A
C: Arm Label: Sequence 1; Type: OTHER; Interventions: Device: High frequency spinal cord stimulation | Arm Label: Sequence 2; Type: OTHER; Interventions: Device: High frequency spinal cord stimulation | Intervention Type: DEVICE; Name: High frequency spinal cord stimulation; Assigned to Arm(s): Sequence 1, Sequence 2
D: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).
Brief Summary: A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy (DPN).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pregabalin 300 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Pregabalin 600 mg/day; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 300 mg/day | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin 600 mg/day
B: Arm Label: ABT-639; Type: EXPERIMENTAL; Interventions: Drug: ABT-639 | Arm Label: pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ABT-639; Assigned to Arm(s): ABT-639 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine Positive Control in Subjects With an Acute Exacerbation of Schizophrenia
Brief Summary: Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing voices) and Negative symptoms (a reduction or absence of normal behaviors or emotions, i.e., unable to manage emotions, make decisions and relate to others). Other symptoms include reduced ability to recall and learn new information, difficulty with problem solving, or maintaining productive employment. The symptoms of schizophrenia may be due to an imbalance in chemicals in the brain, primarily dopamine and serotonin, which enables brain cells to communicate with each other.

Asenapine is an investigational drug that may help to correct the imbalance in dopamine and serotonin. This is a 6 week study to test the efficacy and safety of asenapine and a comparator agent (olanzapine) in the treatment of patients with schizophrenia. Patients that complete this trial will have the option of continuing in an additional one year extension trial.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asenapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asenapine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo arm | Intervention Type: DRUG; Name: Asenapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asenapine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Placebo arm; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: asenapine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Intervention Type: DRUG; Name: asenapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): 3
D: Arm Label: ITI-007 Low Dose; Type: EXPERIMENTAL; Interventions: Drug: ITI-007, Drug: Placebo | Arm Label: ITI-007 High Dose; Type: EXPERIMENTAL; Interventions: Drug: ITI-007 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: ITI-007; Assigned to Arm(s): ITI-007 High Dose, ITI-007 Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): ITI-007 Low Dose, Placebo | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a History of Upper Urinary Tract Infections:a Multicentre Randomised Study
Brief Summary: Our hypothesis is that long-term antimicrobial prophylaxis does not reduce the recurrence of infection and the risk of appearance of kidney scars in children with a documented previous upper UTI.


Options:
A: Intervention Type: DRUG; Name: oral amoxicilline/clavulanic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iv ceftriaxone; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: antibiotic to reduce the recurrence of infection; Assigned to Arm(s): N/A
C: Arm Label: sulfamethoxazole/trimethoprim; Type: EXPERIMENTAL; Interventions: Drug: Sulfamethoxazole/trimethoprim | Arm Label: No prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sulfamethoxazole/trimethoprim; Assigned to Arm(s): sulfamethoxazole/trimethoprim
D: Arm Label: Trimethoprim-Sulfamethoxazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trimethoprim-Sulfamethoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trimethoprim-Sulfamethoxazole; Assigned to Arm(s): Trimethoprim-Sulfamethoxazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries (Thunder - Trial)
Brief Summary: The Thunder Trail is a randomized , double-blinded, placebo controlled German multi-centre study on the efficacy of local paclitaxel for prevention of restenosis in the superficial and popliteal artery.


Options:
A: Intervention Type: DRUG; Name: Balloon Angioplasty with or without drug administration; Assigned to Arm(s): N/A
B: Arm Label: Laser atherectomy and drug-coated balloon; Type: ACTIVE_COMPARATOR; Interventions: Device: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems | Arm Label: Drug eluting Ballon PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems | Intervention Type: DEVICE; Name: Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems; Assigned to Arm(s): Drug eluting Ballon PTA, Laser atherectomy and drug-coated balloon
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Device: paclitaxel coated balloon catheter (device with drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: paclitaxel coated balloon catheter (device with drug) | Intervention Type: DEVICE; Name: paclitaxel coated balloon catheter (device with drug); Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Zilver® PTX™ Drug Eluting Vascular Stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty | Intervention Type: DEVICE; Name: Zilver® PTX™ Drug Eluting Vascular Stent; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Angioplasty; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study on Gait & Motor Function in MS Using BWS Treadmill Training
Brief Summary: The primary purpose of this study is to collect preliminary and pilot data to begin to determine whether the use of body weight support treadmill therapy (BWSTT) with and without driven-gait-orthotics (DGO), results in improved motor recovery and ambulation MS patients with gait impairment


Options:
A: Arm Label: Task-oriented circuit class training; Type: EXPERIMENTAL; Interventions: Behavioral: Task-oriented circuit class training | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: Task-oriented circuit class training; Assigned to Arm(s): Task-oriented circuit class training | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): Usual Care
B: Arm Label: Exercise: Vestibular Rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Exercise: Vestibular Rehabilitation | Arm Label: Exercise Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: Wait-listed Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise: Vestibular Rehabilitation; Assigned to Arm(s): Exercise: Vestibular Rehabilitation | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise Control
C: Arm Label: Endurance training; Type: EXPERIMENTAL; Interventions: Behavioral: Endurance training, Behavioral: Standard care | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Endurance training; Assigned to Arm(s): Endurance training | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Endurance training, Standard care
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Device: Body-weight supported treadmill, Device: Lokomat | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Device: Body-weight supported treadmill, Device: Lokomat | Intervention Type: DEVICE; Name: Body-weight supported treadmill; Assigned to Arm(s): Arm 1 | Intervention Type: DEVICE; Name: Lokomat; Assigned to Arm(s): Arm 1 | Intervention Type: DEVICE; Name: Body-weight supported treadmill; Assigned to Arm(s): Arm 2 | Intervention Type: DEVICE; Name: Lokomat; Assigned to Arm(s): Arm 2

Answer: D